Small Cell Lung Cancer | Norton Healthcare

Indication: Small Cell Lung Cancer

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: EpicentRx (formerly RadioRx)

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.